Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhujiang Hospital

Criteria

Inclusion Criteria:

• First clinical diagnosis of primary liver cancer (China liver cancer staging, CNLC Ia stage);

• Child-Pugh grading standard of liver function was GRADE A or B;

• 18-66 years old;

• Complete clinical case data;

• limited surgical methods (local resection);

• Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

• There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary cerebral renal insufficiency);

• Tumor thrombus or distant metastasis was found in main portal vein and primary branch, main hepatic vein and branch, main hepatic vein and inferior vena cava by preoperative imaging examination;

• planned pregnancy, unplanned pregnancy and pregnancy;

• Preoperative child-Pugh grading standard of liver function was Grade C.

• Disease researchers that the investigator considers inappropriate to participate in this clinical trial.